Gossamer Bio Inc (NAS:GOSS)
$ 0.6833 -0.0107 (-1.54%) Market Cap: 154.57 Mil Enterprise Value: 121.66 Mil PE Ratio: 0 PB Ratio: 5.69 GF Score: 38/100

Gossamer Bio Inc To Discuss TORREY Topline Results Call Transcript

Dec 06, 2022 / 01:00PM GMT
Release Date Price: $2.36 (-74.60%)
Operator

Hello, and welcome to the Gossamer Bio TORREY Topline Results Call. (Operator Instructions) Please note, today's event is being recorded.

I'd now like to turn the conference over to your host today, Faheem Hasnain. Please go ahead.

Faheem Hasnain
Gossamer Bio, Inc. - Co-Founder, CEO, President & Chairman

Hello, everyone, and thank you for joining us this morning. We're here today to discuss a critical milestone in Gossamer and seralutinib history, the positive topline results of the Phase II TORREY study in patients with PAH, Pulmonary Arterial Hypertension.

Most of you have, no doubt, seen the press release we issued this morning announcing our topline results and we're looking forward to diving into the data a bit further with you on the call today.

We'll be making forward-looking statements on this call, and I encourage you to read through the details on the slide.

Now with us from the Gossamer team, we have Dr. Richard Aranda, our Chief Medical Officer; Dr. Rob Roscigno, the clinical lead of the seralutinib

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot